Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Universal Ibogaine Inc ( (TSE:IBO) ) has shared an update.
Universal Ibogaine Inc. announced the resignation of Ken Cranwill from its Board of Directors to focus on other ventures. Additionally, the company has settled a debt of $106,200 in consulting fees owed to CEO Nick Karos by issuing 4,248,000 common shares. This move increases the total number of outstanding shares to 312,858,516. These developments reflect ongoing changes in the company’s leadership and financial strategies, potentially impacting its operational focus and stakeholder relations.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on transforming addiction treatment through medicalized ibogaine. It aims to conduct a Canadian clinical trial targeting opioid use disorder and plans to expand its treatment protocol globally through future licensing agreements. The company is also developing a holistic addiction treatment protocol at its Kelburn Recovery Centre in Manitoba.
Average Trading Volume: 168,292
Technical Sentiment Signal: Sell
Current Market Cap: C$6.32M
For an in-depth examination of IBO stock, go to TipRanks’ Overview page.